There’s something refreshing about tech that restores motion. Not the kind that spins servers or sends data through clouds, but the kind that gives people back the ability to move, to walk, to live on their own terms. Assistive Technology Development, Inc. (ATDev) out of Orange County isn’t just building robotics; they’re building independence. Their flagship device, Reflex™, is a telehealth-enabled robotic system designed to turn knee rehabilitation into an at-home experience that feels personal, adaptive, and, frankly, overdue. This is what happens when exoskeleton engineering collides with empathy and data science in perfect sync.
Co-founders Todd Roberts and Owen Kent didn’t stumble into this. Roberts, now CEO, comes from UC Berkeley’s exoskeleton research program and brings a decade of assistive-tech R&D under his belt. Kent, the CMO, is a serial entrepreneur and disability rights advocate who’s spent his life at the intersection of user experience and lived experience. Together, they turned NIH-backed research into a company that’s as mission-driven as it is technically sophisticated.
Today, ATDev announced a $3.0M seed round led by Dobrzelecki Legacy Ventures, with Uphonest Capital, The Life Science Angels, and a line-up of seasoned angel investors joining the table. That’s not just capital, it’s validation. Validation that the next frontier in rehabilitation isn’t more hospital visits; it’s smarter, safer, connected recovery from home. Reflex™ isn’t a gadget; it’s a bridge between medical precision and everyday usability, powered by AI that personalizes therapy in real-time and learns with every session.
This isn’t theory, it’s already in motion. ATDev’s Reflex™ devices are in beta testing with partners like UCLA Health and UCHealth, part of a nationwide shift toward home-based rehabilitation. The company’s been through MedTech Innovator 2024, Berkeley SkyDeck Batch 14, and the MassRobotics Healthcare Catalyst. That’s three accelerators that don’t just hand out logos, they shape companies that know how to scale and survive.
The $3.0M infusion will power manufacturing scale-up, AI-analytics expansion, and regulatory prep for FDA clearance. The roadmap stretches beyond knees, think joint-specific exoskeletons and predictive-outcome modules that push recovery into the realm of proactive health management. With COO Dave Wilkinson, a 30-year med-device veteran, steering operational scale-up, ATDev isn’t moving cautiously; it’s moving precisely.
For a country with 61M people living with disabilities and 10K turning 65 every day, the market isn’t just big, it’s inevitable. ATDev isn’t chasing a trend; it’s answering a demographic reality with technology that doesn’t just assist but adapts. This seed round is more than funding, it’s momentum for motion, intelligence for independence, and the start of something that moves far beyond robotics.
